Therapeutic Asset Ratings
210 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
MIRZOTAMAB CLEZUTOCLAX
Glioblastoma
Memorial Sloan Kettering Cancer Center
P1
C
(37)
mt-201-gbm monocyte vaccine
Glioblastoma
Michael Gunn
P1
C
(37)
Neukoplast™
Glioblastoma
Johann Wolfgang Goethe University Hospital
P1
C
(37)
nk-92/5.28.z
Glioblastoma
Johann Wolfgang Goethe University Hospital
P1
C
(37)
Ny-Eso-1 157-165
Glioblastoma
Adilia Hormigo
P1
C
(37)
Okn 007
Glioblastoma
University of Oklahoma
P1
C
(37)
Olanzapine
Glioblastoma
National Cancer Institute (NCI)
P1
C
(37)
ONC 206
Glioblastoma
Sabine Mueller, MD, PhD
P1
C
(37)
Personalized Neoantigen Dna Vaccine Supplied By Geneos Therapeutics
Glioblastoma
Washington University School of Medicine
P1
C
(37)
Personalized Neoantigen Peptide Vaccine
Glioblastoma
Dana-Farber Cancer Institute
P1
C
(37)
Plasmid Encoded Il-12
Glioblastoma
Washington University School of Medicine
P1
C
(37)
Rmc-5552
Glioblastoma
Nicholas Butowski
P1
C
(37)
Rqnestin
Glioblastoma
Dana-Farber Cancer Institute
P1
C
(37)
RSC-1255
Glioblastoma
RasCal Therapeutics, Inc.
P1
C
(37)
Selicrelumab
Glioblastoma
Adilia Hormigo
P1
C
(37)
tas2940
Glioblastoma
Taiho Oncology, Inc.
P1
C
(37)
wsd0628
Glioblastoma
Mayo Clinic
P1
C
(37)
18F-ASIS
Glioblastoma
Var2 Pharmaceuticals
Early P1
C
(37)
89zr-dfo-n-suc-c9scfv
Glioblastoma
Var2 Pharmaceuticals
Early P1
C
(34)
89Zr-DFO-N-Suc-F8scFv
Glioblastoma
Var2 Pharmaceuticals
Early P1
C
(34)
Acetadote
Glioblastoma
University of Texas Southwestern Medical Center
Early P1
C
(34)
Bdtx-1535
Glioblastoma
St. Joseph's Hospital and Medical Center, Phoenix
Early P1
C
(34)
Domvanalimab
Glioblastoma
Yale University
Early P1
C
(34)
Fycompa
Glioblastoma
Aarhus University Hospital
Early P1
C
(34)
Ifosfamide
Glioblastoma
Oliver Jonas
Early P1
C
(34)
Showing 176 to 200 of 210 assets
Previous
Page 8 of 9
Next
